Last Updated : April 18, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Demylocan | decitabine | Myelodysplastic Syndromes | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Bosulif (RFA) | Bosutinib | Chronic Myeloid Leukemia | N/A | Complete | ||
| TBD | Trastuzumab | Cancelled | ||||
| Truxima | Rituximab | Cancelled | ||||
| Tysabri | natalizumab | Multiple Sclerosis, relapsing-remitting | Withdrawn | |||
| Aduhelm | aducanumab | Alzheimer’s disease | Withdrawn | |||
| Forxiga | dapagliflozin | Chronic kidney disease | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Doptelet | avatrombopag | Chronic immune thrombocytopenia (ITP) | Active | |||
| Keytruda and Lenvima | pembrolizumab and lenvatinib | Advanced endometrial cancer | Withdrawn | |||
| Clolar | clofarabine | Acute lymphoblastic leukemia | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed |
Last Updated : April 18, 2024